Maze Therapeutics (NASDAQ:MAZE - Get Free Report) announced its quarterly earnings data on Monday. The company reported ($18.32) EPS for the quarter, missing analysts' consensus estimates of ($7.60) by ($10.72), Zacks reports.
Maze Therapeutics Stock Performance
MAZE traded down $0.34 during trading hours on Friday, reaching $8.98. The company's stock had a trading volume of 167,238 shares, compared to its average volume of 300,130. Maze Therapeutics has a 52 week low of $8.33 and a 52 week high of $17.00.
Analyst Upgrades and Downgrades
Several equities research analysts have commented on MAZE shares. JPMorgan Chase & Co. began coverage on shares of Maze Therapeutics in a research report on Tuesday, February 25th. They set an "overweight" rating and a $30.00 price target on the stock. Guggenheim reissued a "buy" rating and set a $19.00 price target on shares of Maze Therapeutics in a research report on Wednesday. TD Cowen raised Maze Therapeutics to a "strong-buy" rating in a research report on Tuesday, February 25th. Leerink Partners began coverage on Maze Therapeutics in a research note on Tuesday, February 25th. They set an "outperform" rating and a $28.00 price objective on the stock. Finally, Leerink Partnrs upgraded shares of Maze Therapeutics to a "strong-buy" rating in a report on Tuesday, February 25th. Three equities research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of "Buy" and an average target price of $25.67.
Get Our Latest Stock Report on MAZE
About Maze Therapeutics
(
Get Free Report)
We are a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular and related metabolic diseases, including obesity. We are advancing a pipeline using our Compass platform, which allows us to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process we refer to as variant functionalization.
Featured Stories
Before you consider Maze Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Maze Therapeutics wasn't on the list.
While Maze Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Get this report to learn how options trading can help you use the market’s volatility to your advantage.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
